Logo
x

Search

Subscribe Now

Daiichi

PharmaShots Weekly Snapshots (July 06 - 10, 2020)

PharmaShots Weekly Snapshots (July 06 - 10, 2020)

  • July 13, 2020
Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20

Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20

  • June 1, 2020
PharmaShots Weekly Snapshot (October 14-18, 2019)

PharmaShots Weekly Snapshot (October 14-18, 2019)

  • October 21, 2019
Daiichi Sankyo and AstraZeneca Dose the First Patient with Adjuvant Datroway in P-III (TROPION-Lung12) Trial for Adenocarcinoma NSCLC

    Daiichi Sankyo and AstraZeneca Dose the First Patient with Adjuvant Datroway in P-III (TROPION-Lung12) Trial for Adenocarcinoma NS...

    • January 31, 2025
    Daiichi Sankyo and AstraZeneca Report the US FDA’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC), Progressed on Endocrine Therapies

      Daiichi Sankyo and AstraZeneca Report the US FDA’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC), Progr...

      • January 28, 2025
      Daiichi Sankyo and AstraZeneca Receives the US FDA Approval for Datroway (Datopotamab Deruxtecan-dlnk) to Treat HR+/HER2- Metastatic Breast Cancer

        Daiichi Sankyo and AstraZeneca Receives the US FDA Approval for Datroway (Datopotamab Deruxtecan-dlnk) to Treat HR+/HER2- Metastat...

        • January 20, 2025
        AstraZeneca and Daiichi Sankyo Report the US FDA’s BLA Acceptance of Datopotamab Deruxtecan with Priority Review for EGFR-mutated NSCLC

          AstraZeneca and Daiichi Sankyo Report the US FDA’s BLA Acceptance of Datopotamab Deruxtecan with Priority Review for EGFR-mutated...

          • January 15, 2025
          Daiichi Sankyo’s Datroway Receives the MHLW’s Approval for Unresectable or Recurrent HR+/HER2- Breast Cancer

            Daiichi Sankyo’s Datroway Receives the MHLW’s Approval for Unresectable or Recurrent HR+/HER2- Breast Cancer

            • December 27, 2024
            Daiichi Sankyo Begins the P-III (QuANTUM-Wild) Study of Vanflyta (Quizartinib) to Treat FLT3-ITD Negative Acute Myeloid Leukemia (AML)

              Daiichi Sankyo Begins the P-III (QuANTUM-Wild) Study of Vanflyta (Quizartinib) to Treat FLT3-ITD Negative Acute Myeloid Leukemia (...

              • December 11, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.